India Examines Regulatory Reforms to Allow Global Pharmaceutical Companies to Conduct First-in-Human Clinical Trials

India is examining changes to its pharmaceutical regulatory framework that could enable multinational drug manufacturers to conduct first-in-human Phase I clinical trials in the country for medicines developed overseas. The proposal forms part of broader efforts to strengthen India’s clinical research capabilities, improve regulatory efficiency and expand its participation in international pharmaceutical innovation.

According to developments reported on 12 November 2026, preliminary discussions have begun among government authorities and pharmaceutical industry stakeholders regarding the regulatory requirements for permitting early-stage clinical trials involving foreign-developed drug molecules. The discussions focus on creating a more clearly defined pathway for such studies while maintaining appropriate scientific evaluation, ethical oversight and patient safety safeguards.

The initiative reflects India’s growing emphasis on moving beyond its established strengths in generic pharmaceutical manufacturing towards greater participation in innovative drug discovery, clinical development and advanced biopharmaceutical research. However, the proposed changes remain under discussion, and no final regulatory amendment specifically permitting a broader category of foreign-origin first-in-human trials has been announced.

Strengthening India’s Early-Stage Clinical Research Capabilities

First-in-human clinical trials represent an important stage in pharmaceutical development, involving the initial administration of an investigational medicine to human participants. These studies generally assess safety, tolerability, pharmacokinetics and, where appropriate, pharmacodynamic effects before a medicine proceeds to larger clinical investigations.

Phase I studies usually involve relatively small groups of participants and are conducted under carefully controlled conditions with intensive monitoring. Depending on the medicine and the disease being investigated, participants may be healthy volunteers or patients with a particular medical condition.

India already possesses clinical research infrastructure and experience in conducting trials across multiple therapeutic areas. However, the regulatory pathways applicable to medicines developed domestically and those discovered outside India differ in important respects.

Under the New Drugs and Clinical Trials Rules, 2019, applications involving new drugs developed abroad generally require submission of available foreign clinical data, including Phase I information where applicable. Regulatory authorities can subsequently evaluate applications for further clinical development in India according to the requirements of the framework.

The reported policy discussions concern the possibility of establishing clearer provisions for conducting initial human studies involving selected foreign-developed medicines within India itself. Such a framework would require regulatory clarity regarding eligibility, scientific justification, safety monitoring and the responsibilities of trial sponsors.

ICMR Identifies Regulatory Challenges in First-in-Human Trials

The Indian Council of Medical Research has already undertaken initiatives to strengthen the country’s capacity for early-stage clinical research.

On 20 May 2026, during the first ICMR Annual Clinical Trial Meet, the Council released a report titled Advancing First-in-Human Phase 1 Clinical Trials in India: A Delphi Study on Regulatory Pathways and Opportunities.

The study was developed through two rounds of consultation involving 37 experts representing pharmaceutical companies, contract research organisations, academic institutions and national regulatory agencies.

The assessment identified regulatory and operational challenges affecting the development of early-phase clinical trials in India. Its recommendations included strengthening regulatory capacity, streamlining approval procedures and improving coordination among institutions involved in clinical research.

The ICMR initiative reflects the growing recognition that advanced clinical research requires specialised infrastructure, scientific expertise, efficient regulatory processes and strong ethical oversight.

The Council also released operational guidelines for a single ethics review of multicentre research, aimed at improving coordination and harmonising ethical review procedures across participating research institutions.

These measures form part of an established national effort to strengthen India’s clinical research environment, independently of the latest reported discussions concerning multinational pharmaceutical companies.

India Develops Dedicated Phase I Clinical Trial Infrastructure

India has been expanding institutional infrastructure to support early-stage pharmaceutical and biomedical research through initiatives led by ICMR and other government organisations.

The ICMR Phase I clinical trial network was established to strengthen national capabilities for evaluating investigational medicines and innovative therapeutic products. Its development has been associated with research projects addressing important public health requirements.

Government-supported programmes have included early-phase investigations involving cancer therapeutics, vaccines and advanced biological treatments. These initiatives demonstrate the application of specialised clinical research infrastructure to products developed through Indian research and industrial partnerships.

The Department of Biotechnology and the Biotechnology Industry Research Assistance Council have also undertaken programmes to strengthen clinical research capabilities, improve regulatory understanding and support innovative biomedical technologies.

In 2026, the Department of Biotechnology reported that BIRAC had convened a strategic consultation titled Strengthening India’s Clinical Trial Regulation: Lessons from Other Countries. The consultation brought together regulatory specialists, clinicians, researchers, pharmaceutical industry representatives and international experts to examine approaches to clinical trial governance.

The discussions included early-phase and first-in-human studies, regulatory approaches for emerging therapies and lessons from international clinical research systems.

A white paper was developed to capture the regulatory reforms identified through the consultation process.

Regulatory Modernisation Under New Drugs and Clinical Trials Framework

India has already introduced regulatory changes designed to simplify certain pharmaceutical research and development procedures.

In January 2026, the Ministry of Health and Family Welfare notified amendments to the New Drugs and Clinical Trials Rules, 2019, aimed at reducing procedural requirements for selected pharmaceutical research activities.

The amendments replaced the requirement for prior test licences with a system of online intimation for certain categories of drugs manufactured in small quantities for analytical and non-clinical testing. Specified higher-risk categories remain subject to regulatory permission.

For categories continuing to require test licences, the statutory processing period was reduced from 90 days to 45 days.

The amendments also simplified approval requirements for certain low-risk bioavailability and bioequivalence studies, allowing eligible activities to proceed through a notification mechanism.

The Government stated that these reforms were intended to reduce regulatory delays, improve the efficiency of pharmaceutical development and strengthen India’s attractiveness as a destination for pharmaceutical research.

These notified changes are distinct from the newly reported proposal concerning first-in-human trials involving foreign-developed molecules, which has not yet resulted in a confirmed regulatory amendment.

Bio Pharma Shakti to Expand India’s Clinical Research Ecosystem

India’s clinical research ambitions are also supported by the Bio Pharma Shakti initiative announced in the Union Budget 2026–27.

The programme envisages an investment of ₹10,000 crore over five years to strengthen domestic capabilities in biopharmaceutical research, development and manufacturing.

An important component of the initiative is the proposed establishment of a national network of 1,000 accredited clinical trial sites, intended to expand the country’s ability to undertake advanced clinical research.

The programme also includes the establishment of three additional National Institutes of Pharmaceutical Education and Research and the upgradation of seven existing institutes.

These measures are intended to strengthen specialised scientific education, pharmaceutical research and the availability of trained personnel required for advanced biopharmaceutical development.

The Government has also identified the need to strengthen the Central Drugs Standard Control Organisation through additional scientific and technical expertise, particularly for evaluating complex biopharmaceutical products.

Together, these initiatives provide an institutional foundation for India’s broader efforts to expand its participation in innovative drug development.

Greater Regulatory Clarity for Foreign-Developed Medicines

One of the principal issues surrounding the proposed reforms is the regulatory treatment of investigational medicines discovered or developed outside India.

The existing framework distinguishes between applications involving domestically developed medicines and those supported by clinical investigations conducted overseas.

Industry representatives have identified the need for more detailed guidance covering the circumstances in which foreign-developed medicines could enter first-in-human studies in India.

Such guidance would need to address scientific assessment, preclinical evidence, risk evaluation, trial-site preparedness, informed consent and participant protection.

Regulatory authorities would also need to determine the circumstances under which early-phase studies could be conducted concurrently with international clinical development programmes.

The current discussions therefore concern not simply the geographical location of clinical trials but the scientific and regulatory framework governing the earliest stages of human drug testing.

Any eventual change would require a formal regulatory decision and clearly established safeguards before implementation.

India Seeks a Greater Role in Global Drug Innovation

India’s pharmaceutical industry has developed substantial manufacturing capabilities, particularly in generic medicines, vaccines and pharmaceutical ingredients. The expansion of innovative drug research represents a further area of policy attention as the country seeks to strengthen its position in the global pharmaceutical value chain.

Advanced clinical research requires coordinated capabilities in drug discovery, preclinical evaluation, clinical pharmacology, specialised laboratory services, regulatory science and patient safety monitoring.

The Government’s existing initiatives through ICMR, CDSCO, the Department of Biotechnology and BIRAC reflect efforts to strengthen these capabilities and support the development of innovative medicines within India.

The reported discussions on permitting a broader range of foreign-origin first-in-human studies are consistent with this wider emphasis on regulatory modernisation and clinical research capacity building.

For multinational pharmaceutical companies, a clearer regulatory pathway could make India an additional location for early-stage drug development, subject to scientific, operational and regulatory requirements.

The timing and scope of any such change will depend on the outcome of the ongoing policy discussions and subsequent regulatory decisions.

Strengthening India’s Position in International Pharmaceutical Research

The consideration of first-in-human clinical trial reforms represents another development in India’s efforts to expand its pharmaceutical research and innovation ecosystem.

The country’s existing clinical research infrastructure, the ICMR Phase I network, regulatory modernisation initiatives and planned expansion of accredited trial facilities provide important foundations for advancing early-stage drug development.

The proposed policy changes concerning foreign-developed medicines remain at a preliminary stage, with no final decision or implementation schedule officially announced.

As India continues to strengthen scientific research, clinical infrastructure and pharmaceutical regulation, the development of clear and internationally credible pathways for innovative drug trials remains an important area of national policy attention.

---